These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28338752)

  • 1. Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme.
    Smith LM; Lévesque LE; Kaufman JS; Strumpf EC
    Int J Epidemiol; 2017 Jun; 46(3):939-949. PubMed ID: 28338752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression discontinuity designs in epidemiology: causal inference without randomized trials.
    Bor J; Moscoe E; Mutevedzi P; Newell ML; Bärnighausen T
    Epidemiology; 2014 Sep; 25(5):729-37. PubMed ID: 25061922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression discontinuity design for the study of health effects of exposures acting early in life.
    Popovic M; Zugna D; Tilling K; Richiardi L
    Front Public Health; 2024; 12():1377456. PubMed ID: 38706545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study.
    Mihretie GN; Liyeh TM; Ayele AD; Belay HG; Yimer TS; Miskr AD
    Reprod Health; 2022 Jun; 19(1):136. PubMed ID: 35689288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.
    Lim ASE; Lim RBT
    Vaccine; 2019 Sep; 37(41):6030-6038. PubMed ID: 31473002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
    Kim JJ; Goldie SJ
    BMJ; 2009 Oct; 339():b3884. PubMed ID: 19815582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda.
    Ngcobo NJ; Burnett RJ; Cooper S; Wiysonge CS
    S Afr Med J; 2018 Dec; 109(1):13-15. PubMed ID: 30606297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).
    Young EJ; Tabrizi SN; Brotherton JM; Wark JD; Pyman J; Saville M; Wrede CD; Jayasinghe Y; Tan J; Gertig DM; Pitts M; Garland SM
    BMC Cancer; 2013 Jun; 13():296. PubMed ID: 23777549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of human papilloma virus vaccination on sexual behaviours among adolescent women in Rwanda: a regression discontinuity study.
    Hategeka C; Ogilvie G; Nisingizwe MP; Rulisa S; Law MR
    Health Policy Plan; 2020 Oct; 35(8):1021-1028. PubMed ID: 32830261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
    Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes.
    Garnett GP; Kim JJ; French K; Goldie SJ
    Vaccine; 2006 Aug; 24 Suppl 3():S3/178-86. PubMed ID: 16950005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
    Jiang Y; Ni W; Wu J
    BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.